ATS 2020 Advance Program

• familiarize current clinical controversies in the diagnosis and management of PAH; • better diagnose PAH and differentiate it from pulmonary venous hypertension; • familiarize the indications for testing RV reserve in patients with PAH. The goal of this session is to discuss and highlight controversies in the diagnosis and management of PAH patients. While the knowledge about PAH has greatly improved over the last decades, numerous clinical questions remain about how patients should be diagnosed and treated. Chairing: S. Provencher, MD, Quebec city, Canada C.E. Ventetuolo, MD, MSCR, Providence, RI P.A. Thistlethwaite, MD, PhD, La Jolla, CA T. Thenappan, MD, Minneapolis, MN 9:15 Patients with Mild Pulmonary Hypertension (mPAP 21-24) SHOULD Be Treated with Pulmonary Vasodilators D.M. Systrom, MD, Boston, MA 9:30 Patients with Mild Pulmonary Hypertension (mPAP 21-24) SHOULD NOT Be Treated with Pulmonary Vasodilators H.W. Farber, MD, Boston, MA 9:45 Right Heart Catheterization Is Fundamental in the Follow-Up Management of Patients with Pulmonary Hypertension M. Gomberg-Maitland, MD, MSc, Washington, DC 10:00 Non-Invasive Imaging Including Echo and Cardiac MRI Is Adequate for Follow-Up Testing in Patients with Pulmonary Hypertension D. Kiely, MD, Sheffield, United Kingdom 10:15 Initial Triple Therapy Should Be Considered for All Newly Diagnosed PAH Patients O. Sitbon, MD, ScD, Le Kremlin - Bicetre, France 10:30 Sequential Therapy with Rapid Treatment Escalation Based on Risk Scores Remains the Treatment of Choice for Non-High Risk Patients I.R. Preston, MD, Boston, MA 10:45 Riociguat Should Be Given to All CTEPH Patients, Regardless of Timing of PEA K.M. Kerr, MD, La Jolla, CA 11:00 Riociguat Should Be Given Only to Patients with Inoperable or Residual CTEPH After Surgical Pulmonary Thromboendarterectomy I.M. Lang, MD PhD, Vienna, Austria TRANSLATIONAL SCIENTIFIC SYMPOSIUM C6 AN INTEGRATED SYSTEM: IMPACTS OF SKELETAL MUSCLE AND CARDIAC PHYSIOLOGY IN COPD Assemblies on Pulmonary Rehabilitation; Respiratory Structure and Function 9:15 a.m. - 11:15 a.m. Target Audience Physicians managing chronic respiratory disease; pulmonary rehabilitation practitioners, pulmonary and exercise physiologists. Objectives At the conclusion of this session, the participant will be able to: • understand the causes and consequences of abnormal lung, cardiac and skeletal muscle physiology in COPD; • offer the molecular and cellular basis leading to the design of novel therapeutic strategies to better treat the systemic manifestations and/or comorbities in chronic respiratory and cardiac disease; • provide knowledge on the most recent technical advances in therapeutic strategies: nutritional support and other technological achievements in pulmonary rehabilitation and physical activity promotion. This session will provide a broad and expert overview of the clinical impact of cardiac, lung and skeletal muscle dysfunction in COPD. Speakers will draw on recent advances in understanding of basic science to discuss the outstanding issues in these fields, specifically the aetiology of skeletal muscle ATS 2020 • Philadelphia, PA TUESDAY • MAY 19 103